^
    Back
    Association details:
    Biomarker:SSTR positive
    Cancer:Neuroendocrine Tumor
    Drug:Mycapssa (octreotide) (SSTR agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ASCO.org
    Title:

    Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline

    Published date:
    09/29/2023
    Excerpt:
    SSAs (octreotide or lanreotide) are recommended for SSTR-positive and/or functional metastatic G1-grade 2 (G2) GI-NETs…
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Excerpt:
    Bronchopulmonary/Thymus Neuroendocrine Tumors…Pancreatic Neuroendocrine Tumors (Well-Differentiated Grade 1/2): Preferred Regimens...Octreotide, LAR or lanreotide (if SSR-positive and/or hormonal symptoms).
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Excerpt:
    SSAs can be recommended as first-line therapy for tumour growth control in advanced, slowly-growing SSTR-positive GI and Pan-NETs up to a Ki-67 of 10% [I,A; ESMO-MCBS v1.1 score: 3] for lanreotide and [I, A; ESMO-MCBS v1.1 score: 2] for octreotide.